Anti-parasitic drug slows pancreatic cancer in mice 抗寄生蟲藥可減緩小鼠胰腺癌

Editor’s note:  Many parasites and microbes including fungi, bacteria and viruses can cause a variety of cancer.  The scientific community has already acknowledge the fact even though the medical circle pretends the link does not exist.  Sporadic reports indicate that some anti-parasitic and antifungal drugs may be very effective at curing cancer. For instance, naturally occurring anti0fungal compounds found in carrots are very potent anticancer medicine.  An anti-parasitic drug fenbendazole used to treat dogs proves effective at curing some cancers in humans.  The compound used for the current study mebendazole, which is similar to fenbendazole is no doubt an effective anticancer drug.
編者按:許多寄生蟲和微生物,包括真菌、細菌和病毒,都會導致多種癌症。 儘管醫學界假裝這種聯繫不存在,但科學界已經承認了這一事實。 零星報告表明,一些抗寄生蟲和抗真菌藥物可能對治療癌症非常有效。 例如,在胡蘿蔔中發現的天然抗真菌化合物是非常有效的抗癌藥物。 一種用於治療狗的抗寄生蟲藥芬苯達唑被證明可有效治療人類的某些癌症。 本次研究中使用的與芬苯達唑類似的化合物甲苯咪唑無疑是一種有效的抗癌藥物。
News Release

Johns Hopkins study: Anti-parasitic drug slows pancreatic cancer in mice

Peer-Reviewed Publication

Johns Hopkins Medicine

Mouse pancreas with cancer
image: The image on the left (Control) is a magnified view of an example mouse pancreas that has developed pancreatic cancer due to mutations in cancer susceptibility genes and an inflammatory agent. On the right (MBZ) is the same mouse strain treated with the same inflammatory agent, but mebendazole was added to the same mouse feed, and it has little or no microscopic evidence of cancer or pathology. view more 

Credit: Tara Williamson

FOR IMMEDIATE RELEASE

As the third-most lethal cancer in the United States, with only a 1% five-year survival rate for people with its most aggressive form, pancreatic cancer has long been a target of researchers who search for ways to slow or stop its growth and spread. Now, a team of Johns Hopkins Medicine researchers have found that an anti-parasitic drug prevents pancreatic cancer’s initiation, progression and metastasis in genetically engineered mice.

In a study published in the journal Oncotarget on July 6, Gregory Riggins, M.D., Ph.D., professor of neurosurgery and oncology at the Johns Hopkins University School of Medicine, and his team used two different mouse models to determine that the anti-parasitic drug mebendazole could slow or stop the growth and spread of both early and late-stage pancreatic cancer.

“We think that mebendazole could have a role in all stages,” Riggins says. “It was particularly effective for pancreatic cancer that was detected early.”

Riggins and his team administered mebendazole to mice that were genetically engineered to develop pancreatic cancer. The team measured the inflammation and the change in tissue, as well as the stage, grade and metastatic status in each tumor.

Originally used to fight roundworm, hookworm and other parasitic infections by cutting off the parasites’ supply of nutrition, mebendazole inhibits the formation of tubulin. Tubulin, Riggins explains, is both a micro-skeleton of the inner cell and a highway for transport. The drug gets into the parasite’s gut and collapses the tubulin, starving the parasite to death. The study shows that mebendazole may act similarly in pancreatic cancer by collapsing cancer cells’ structure, along with other mechanisms such as reducing inflammation.

Riggins says he hopes to continue his team’s research through human clinical trials.

“We are advocating for use of mebendazole as a therapy for those diagnosed before metastasis to see if we can slow or prevent pancreatic cancer,” Riggins says. “For those with more advanced cancers, it could be an alternative to certain surgeries. Mebendazole may have utility as a therapy after initial treatment to prevent tumor recurrence in the 15% to 20% of pancreatic adenocarcinoma patients who undergo surgery. It may also increase the durability of response to standard chemotherapy in the remaining 80% to 85% of patients with advanced disease.”

###

The Virginia and D.K. Ludwig Fund for Cancer Research provided funding for the research.

Other scientists who conducted the research include Tara Williamson, Michelle Carvalho de Abreu, Dimitri G. Trembath, Cory Brayton, Byunghak Kang, Thais Biude Mendes, Paulo Pimentel de Assumpção and Janete M. Cerutti.

Riggins and Williamson are inventors on intellectual property related to mebendazole owned and managed by Johns Hopkins University conflict of interest policies. Riggins has a financial interest in Benizole Therapeutics, PBC.

The technology is available for licensing through Johns Hopkins Technology Ventures.

$$$ 如果你愿意,你可以在这捐款支持我们。谢谢。$$$
$$$ If you would, you can make a donation here to support us. Thank you. $$$

9

No Responses

Write a response

3 × 4 =